The company is divesting most of its global commercial rights to a suite of five medications.
News & Analysis: AstraZeneca
Shares of the pharmaceutical giant are down 4.3% in light of the news.
AZN earnings call for the period ending December 31, 2019.
A decision on Roxadustat should arrive by Dec. 20.
Analysts at investment bank Raymond James theorize that the trend will continue.
Strong late-stage clinical trial results are helping bolster this blood thinner's appeal.
Despite the company's best efforts, England's top regulators say the drug is too expensive.
The blockbuster drug is already approved for three other types of tumors.
The British drugmaker throws in the towel on a study that could have positioned Epanova to compete against Amarin's Vascepa.
The FDA was in a big hurry to make these new therapies available for patients who need them.